| ritonavir / Generic mfg. |
ChiCTR2000030000: An open, controlled clinical trial for evaluation of ganovo combined with ritonavir and integrated traditional Chinese and Western medicine in the treatment of novel coronavirus infection (COVID-19) |
|
|
| Recruiting | 4 | 50 | | Ganovo/ ritonavir oral ;Pegasys injection ;Novaferon intramuscular injection+Spray inhalation ;Coriolus oral ;TCM+Spray inhalation | Nanchang Ninth Hospital; Nanchang Ninth Hospital, Ascletis Pharmaceuticals CO., LTD. | Pneumonia caused by new coronavirus | | | | |
2016-002700-78: Behaviour of ritonavir in the gastrointestinal tract of healthy volunteers Gedrag van ritonavir in het gastrointestinaal stelsel van gezonde vrijwilligers |
|
|
| Ongoing | 4 | 10 | Europe | Norvir, Syrup, Tablet, NORVIR siroop (80 mg / mL), NORVIR 100 mg tabletten | KU Leuven - Drug Delivery and Disposition, KU Leuven | Healthy human volunteers Gezonde vrijwilligers, Healthy human volunteers Gezonde vrijwilligers, Body processes [G] - Digestive System and Oral Physiological Phenomena [G10] | | | | |
2016-001440-18: The influence of cytochrome P450 3A4 inhibitors on serum levels of Ivacaftor in cystic fibrosis patients and healthy subjects. De invloed van cytochroom P450 3A4 remmers op bloedspiegels van ivacaftor in patiënten met taaislijmziekte en gezonde vrijwilligers. |
|
|
| Ongoing | 4 | 12 | Europe | Claritromycin, azithromycin, Norvir, Film-coated tablet, Ivacaftor, claritromycin 500mg film coated tablets, Azithromycin 500 mg film-coated tablet, Norvir 100 mg film-coated tablets | university medical center utrecht, University medical center utrecht | cystic fibrosis and healthy subjects, patients with cystic fibrosis and healthy people, Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16] | | | | |
ChiCTR2000029867: The efficacy and safety of carrimycin treatment in patients with novel coronavirus pneumonia (COVID-19): a multicenter, randomized, open-label, controlled trial |
|
|
| Recruiting | 4 | 520 | | Carrimycin ;Lopinavir and Ritonavir Tablets | Beijing You'an Hospital, Capital Medical University; Bejing You'an Hospital, Capital Medical University, Ministry of Science and Technology of the People's Republic of China | Novel Coronavirus Pneumonia (COVID-19) | | | | |
2018-004854-12: Investigation of the blood levels at a reduced dose of erlotinib with the addition of ritonavir compared to the normal dose of erlotinib Onderzoek naar de bloedwaardes bij een verlaagde dosis erlotinib met toevoeging van ritonavir in vergelijking met de normale dosering erlotinib |
|
|
| Not yet recruiting | 4 | 10 | Europe | Erlotinib, Ritonavir, L01XE03, J05AE03, Tablet, Tarceva, Norvir | Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis, Stichting Het Nederlands Kanker Instituut-Antoni van Leuewenhoek Ziekenhuis | Advanced EGFR mutation positive non small cell lung cancer, pancreatic carcinoma, colorectal cancer and biliary cancer Gevorderd EGFR mutatie positief niet-kleincellig longkanker, pancreascarcinoom, colorectaal kanker en galwegkanker, non small cell lung cancer, pancreatic carcinoma, colorectal cancer and biliary cancer niet-kleincellig longkanker, pancreaskanker, darmkanker en galwegkanker, Diseases [C] - Cancer [C04] | | | | |
| Active, not recruiting | 4 | 155 | RoW | Darunavir (DRV) 800 milligram (MG) Oral Tablet, Prezista, Ritonavir 100 MG Oral Tablet, Norvir, RTV, N(t)RTIs, Nucleoside/nucleotide reverse transcriptase inhibitors [N(t)RTIs], Dolutegravir 50 MG Oral Tablet, Tivicay, DTG, TDF 300 MG Oral Tablet, tenofovir disoproxil fumarate, Viread, 3TC 300 MG Oral Tablet, lamivudine, FTC 200 MG Oral Cap, Emtriva, emtricitabine | Kirby Institute | HIV Infections | 01/24 | 01/24 | | |
NCT06337032: A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments |
|
|
| Recruiting | 4 | 350 | RoW | F/TAF (High Dose Tablet), Descovy®, F/TAF (Low Dose Tablet), F/TAF (Lowest Dose Tablet), F/TAF (High Dose TOS), F/TAF (Low Dose TOS), F/TAF (Lowest Dose TOS), E/C/F/TAF, Genvoya®, E/C/F/TAF (Low Dose), Cobicistat (High Dose), GS-9350, Tybost®, Cobicistat (Low Dose), Cobicistat (TOS), B/F/TAF (High Dose), Biktarvy®, GS-9883/F/TAF, B/F/TAF (Low Dose), B/F/TAF (High Dose TOS), B/F/TAF (Low Dose TOS), B/F/TAF (Lowest Dose TOS), 3rd ARV Agent, Nucleos(t)ide reverse transcriptase inhibitors (NRTI), ATV, DRV, Lopinavir Boosted with ritonavir (LPV/r) | Gilead Sciences | HIV-1-infection | 03/34 | 03/34 | | |
2006-004476-12: A randomised open-label study comparing the safety and efficacy of three different combination antiretroviral regimens as initial therapy for HIV infection. |
|
|
| Ongoing | 3/4 | 80 | Europe | Truvada, Efavirenz, Ritonavir, Atazanavir sulfate, Abacavir sulfate, Zidovudine, Truvada, Efavirenz, Ritonavir, Atazanavir sulfate, Abacavir sulfate, Zidovudine, Truvada, Efavirenz, Ritonavir, Atazanavir sulfate, Abacavir sulfate, Zidovudine | University of New South Wales | Chronic HIV infection | | | | |
2013-002573-22: PROBE TRIAL proof-of-concept study on the use of rilpivirine as substitutive agent for the HAART nucleosidic backbone in virologic suppressed patients STUDIO PROBE rivolto a pazienti con infezione da HIV tratatti con una combinazioen di tre farmaci( due nucleosidici ed un inibitore della proteasi) e che presentano una risposta ottimale con mancata replicazione stabile del virus HIV |
|
|
| Ongoing | 3 | 60 | Europe | Coated tablet, Edurant, Prezista, Norvir | A.O PAPA GIOVANNI XXIII- BERGAMO, janssen | HIV1-infected adults pazienti con infezione HIV, HIV1-infected adults of ≥ 18 years of age on an effective ARV therapy (HIV-RNA < 50 copies/ml) based on the use of two NRTIs and a boosted-PI Adulti con infezione da HIV1 di età ≥ 18 anni con un efficace terapia ARV (HIV-RNA <50 copie / ml), basato sull'utilizzo di due NRTI e un potenziato-PI, Diseases [C] - Immune System Diseases [C20] | | | | |
2020-003951-13: Dual therapy in HIV patients in 4 days a week versus 7 days a week Bithérapie chez des patients HIV en 4 jours sur 7 versus 7 jours sur 7 |
|
|
| Not yet recruiting | 3 | 440 | Europe | Film-coated tablet, TIVICAY, EPIVIR, PREZISTA, EDURANT, NORVIR | INSERM-ANRS, ANRS | HIV infection Infection par le VIH, HIV infection Infection par le VIH, Diseases [C] - Virus Diseases [C02] | | | | |
| Completed | 3 | 407 | Europe, Canada, US, RoW | Lonafarnib, EBP994, Sarasar, LNF, Ritonavir, Norvir, RTV, PEG IFN-alfa-2a, Pegasys, pegylated interferon-alfa, Placebo Lonafarnib, Placebo Ritonavir | Eiger BioPharmaceuticals | Hepatitis Delta Virus | 10/22 | 03/23 | | |
NCT03727152: Switching From Protease Inhibitor/Ritonavir to Generic Single Tablet Regimen of Tenofovir Alafenamide/Emtricitibine/Dolutegravir |
|
|
| Completed | 3 | 170 | RoW | generic single tablet TAF/FTC/DTG | The HIV Netherlands Australia Thailand Research Collaboration, Faculty of Medical Sciences, Radboud University of Medical Center, Department of Pharmaceutical care, Faculty of Pharmacy, Chiang Mai University, Police General Hospital | HIV | 04/23 | 04/23 | | |
ChiCTR2200062792: A Multicenter, Randomized, Double-blind, Phase II/III Clinical Study to Evaluate the Efficacy and Safety of SIM0417 Orally Co-Administered with Ritonavir in Symptomatic Adult Participants with Mild to Moderate COVID-19 |
|
|
| Not yet recruiting | 3 | 1200 | | orally administrated SIM0417+ ritonavir ;SIM0417 tablet, ritonavir tablet | China-Japan Friendship Hospital; Jiangsu Xiansheng Pharmaceutical Co., Ltd., self-finance | COVID-19 | | | | |
LOWR6, NCT05229991: Once Daily Dosing of Lonafarnib Co-administered With Ritonavir for Treatment of Chronic Hepatitis D Virus Infection |
|
|
| Active, not recruiting | 3 | 30 | RoW | Lonafarnib, LNF, Ritonavir, Norvir | Soroka University Medical Center, Eiger BioPharmaceuticals | Hepatitis D, Chronic | 12/24 | 04/25 | | |
NCT05506176: A Clinical Study to Evaluate the Efficacy and Safety of SIM0417 Orally Co-Administered With Ritonavir in Symptomatic Adult Participants With Mild to Moderate COVID-19 |
|
|
| Completed | 2/3 | 1208 | RoW | SIM0417, Simnotrelvir, Placebo | Jiangsu Simcere Pharmaceutical Co., Ltd. | COVID-19 | 01/23 | 03/23 | | |
ChiCTR2200067088: A International Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase II/III Clinical Study to Evaluate the Efficacy and Safety of GST-HG171/Ritonavir in Patients With Mild to Moderate COVID-19 |
|
|
| Recruiting | 2/3 | 1200 | | GST-HG171 tablets combined with ritonavir ;Placebo | The First Affiliated Hospital of Guangzhou Medical University; The Third People's Hospital of Shenzhen; The First Affiliated Hospital of Guangzhou Medical University, Fujian Akeylink Biotechnology Co., Ltd. | mild to moderate COVID-19 | | | | |
NCT05656443: Study of GST-HG171/Ritonavir Compared With Placebo in Patients With Mild to Moderate COVID-19 |
|
|
| Completed | 2/3 | 1246 | RoW | GST-HG171/Ritonavir, Placebo | Fujian Akeylink Biotechnology Co., Ltd. | COVID-19 Pneumonia | 05/23 | 07/23 | | |
NCT04147208: Evaluate the Safety, Tolerability, and Antiviral Activity of GLS4 With Ritonavir in Patients With Chronic HBV Infection |
|
|
| Completed | 2 | 250 | RoW | GLS4, Morphothiadine Mesilate Capsules, RTV, Ritonavir tablet, ETV, Entecavir table | Sunshine Lake Pharma Co., Ltd. | Chronic HBV Infection | 06/22 | 09/23 | | |
| Recruiting | 2 | 400 | Europe | Nirmatrelvir/ritonavir, Paxlovid, Placebo/ritonavir, Placebo | Karolinska Institutet, Karolinska University Hospital, Pfizer | Post-COVID-19 Syndrome, Long COVID, Long Covid19, COVID-19, POTS - Postural Orthostatic Tachycardia Syndrome, Post COVID-19 Condition, Post-COVID Syndrome, Post COVID-19 Condition, Unspecified, Postinfectious Inflammation, Postinfectious Disorder | 01/24 | 03/24 | | |
NCT05953545: Peginterferon Lambda and Lonafarnib Boosted With Ritonavir 48-Week Combination Therapy for Delta Hepatitis |
|
|
| Withdrawn | 2 | 30 | US | Peginterferon Lambda | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Chronic Hepatitis Delta | 05/24 | 05/24 | | |
NCT05369676: To Evaluate SSD8432/ Ritonavir in Adults With COVID-19 |
|
|
| Completed | 1/2 | 32 | RoW | SSD8432 dose 1/Ritonavir, SIM0417 dose 1/Ritonavir, SSD8432 dose 2/Ritonavir, SIM0417 dose 2/Ritonavir | Jiangsu Simcere Pharmaceutical Co., Ltd. | COVID-19 Patients | 08/22 | 08/22 | | |
2021-001029-32: A Phase 1/2 Study of PBI-200 in Subjects with NTRK-Fusion-Positive Advanced or Metastatic Solid Tumors |
|
|
| Not yet recruiting | 1/2 | 91 | Europe | PBI-200, ritonavir, PBI-200, Tablet, Film-coated tablet, Norvir | Pyramid Biosciences, Inc., Pyramid Biosciences, Pyramid Biosciences, Inc., Pyramid Biosciences | One of the following solid tumors which has progressed on or following at least one systemic therapy regimen administered for advanced or metastatic disease or for which no approved therapy exists:• NTRK-fusion-positive, locally advanced (i.e., not amenable to surgical resection) or metastatic solid tumor• NTRK-gene amplified, locally advanced or metastatic solid tumor (Phase 1 only)• EWSR1-WT1-positive DSRCTs (Phase 1 only), Subjects with NTRK-Fusion-Positive Advanced or Metastatic Solid Tumors, Diseases [C] - Cancer [C04] | | | | |
| Recruiting | 1/2 | 766 | US, RoW | DB-1303/BNT323, Pertuzumab Injection, Ritonavir, Itraconazole | DualityBio Inc., BioNTech SE | HER2-positive Advanced Solid Tumor | 04/26 | 10/27 | | |
ACTRN12611001058965: An open-labeled, randomized, crossover, multi-dose study in healthy male subjects to test the pharmacokinetics (how your body handles the drug e.g. how it absorbs it and how it eliminates it), safety, and tolerability of investigational drugs taken, with a pharmacokinetics comparison to the combination of the marketed drug Reyataz (Registered Trademark) and Norvir (Registered Trademark) |
|
|
| Not yet recruiting | 1 | 36 | | | CoNCERT Pharmaceuticals, CoNCERT Pharmaceuticals | Treatment of HIV | | | | |
ChiCTR-IIR-16008284: Randomized, Double-blind, Parallel, Entecavir-controlled, Multiple-Dose Study to Evaluate the Safety, Pharmacokinetics and Antiviral Activity of Morphothiadine Mesilate Capsules/Ritonavir Tablets in Patients with Chronic Hepatitis B |
|
|
| Recruiting | 1 | 24 | | 120mgGLS4/100mgRTV, QD ;240mgGLS4/100mgRTV, QD ;0.5mgETV, QD | Jilin University First Hosptal; Jilin university first hosptal, self-funding | chronic hepatitis B | | | | |
A104, NCT03383692: Study of DS-8201a for Participants With Advanced Solid Malignant Tumors |
|
|
| Completed | 1 | 40 | Japan, RoW | DS-8201a, Ritonavir, Norvir, Itraconazole, Sporanox, Orungal | Daiichi Sankyo Co., Ltd., AstraZeneca | Neoplasm Metastasis | 09/18 | 09/23 | | |
NCT05829551: The Safety, Tolerability and Pharmacokinetics Study of RAY1216 in Healthy Adult Participants |
|
|
| Completed | 1 | 88 | RoW | RAY1216 dose 1, RAY1216 dose 2, RAY1216 dose 3, RAY1216 dose 4 &ritonavir, RAY1216 dose 5, RAY1216 dose 6, RAY1216 dose 7, RAY1216 dose 8, RAY1216 dose 9, RAY1216 dose 10 | Guangdong Raynovent Biotech Co., Ltd | COVID-19 (Coronavirus Disease 2019) | 08/22 | 08/22 | | |
NCT05458076: A Study of QLS1128 and in Combination With Ritonavir in Healthy Participants |
|
|
| Recruiting | 1 | 86 | RoW | QLS1128 A-Dose 1~5 and Ritonavir, QLS1128 C-Dose 1~3 and Ritonavir, QLS1128 D-Dose 1 and Ritonavir | Qilu Pharmaceutical Co., Ltd. | COVID-19 | 09/22 | 09/22 | | |
NCT05339646: A Phase I Clinical Study of SSD8432 in Healthy Adult Subjects |
|
|
| Recruiting | 1 | 108 | RoW | SSD8432 dose 1~7 and Ritonavir, SSD8432 dose 8~9, SSD8432 dose 10~12 and ritonavir, SSD8432 dose 13 and Ritonavir, SSD8432 dose 14 and Ritonavir | Jiangsu Simcere Pharmaceutical Co., Ltd. | Healthy Participants | 10/22 | 12/22 | | |
| Completed | 1 | 108 | RoW | WPV01 Dose 1-4, WPV01 Dose 5-8 and Ritonavir, WPV01 Dose 9-12, WPV01 Dose 13-15 and Ritonavir, WPV01 Dose 16 | Westlake Pharmaceuticals (Hangzhou) Co., Ltd. | Healthy Participants | 03/23 | 07/23 | | |
NCT02437110: HERV-K Suppression Using Antiretroviral Therapy in Volunteers With Amyotrophic Lateral Sclerosis (ALS) |
|
|
| Completed | 1 | 122 | US | Darunavir, Ritonavir, Dolutegravir, Tenofovir alafenamide (TAF) | National Institute of Neurological Disorders and Stroke (NINDS) | Amyotrophic Lateral Sclerosis | 11/22 | 05/23 | | |
NCT05665647: Drug-Drug Interaction Study of Itraconazole, Rifampicin and Midazolam With SIM0417/Ritonavir in Healthy Participants |
|
|
| Completed | 1 | 36 | RoW | Cohort 1: SIM0417/ritonavir and itraconazole, Interaction between SIM0417/ritonavir and itraconazole, Cohort 2: SIM0417/ritonavir and rifampicin, Interaction between SIM0417/ritonavir and rifampicin, Cohort 3: SIM0417/ritonavir and midazolam, Interaction between SIM0417/ritonavir and midazolam | Jiangsu Simcere Pharmaceutical Co., Ltd. | Healthy Volunteers | 01/23 | 02/23 | | |
NCT06084507: Food Effects of GST-HG171 Tablets Combined With Ritonavir in Healthy Chinese Participants |
|
|
| Active, not recruiting | 1 | 18 | RoW | GST-HG171/ritonavir, ritonavir | Fujian Akeylink Biotechnology Co., Ltd. | COVID-19 Respiratory Infection | 05/23 | 12/23 | | |
ChiCTR2300068646: Bioequvalence research of Nematavir Tablets/Ritonavir Ttablets (co-packaged) in in healthy people (under fed condition) |
|
|
| Not yet recruiting | 1 | 36 | | T-R-T-R ;R-T-R-T | Yue Bei People's Hospital; Yue Bei People's Hospital, Changsha Duxact Biotech Co. | Healthy people | | | | |
NCT06087055: Drug-Drug Interaction Study of Itraconazole With GST-HG171/Ritonavir in Healthy Participants |
|
|
| Completed | 1 | 12 | RoW | GST-HG171/Ritonavir, Itraconazole | Fujian Akeylink Biotechnology Co., Ltd. | Healthy Participant | 06/23 | 08/23 | | |
NCT05826249: Safety and Pharmacokinetics of SIM0417 Combined With Ritonavir in Healthy Elderly Subjects |
|
|
| Recruiting | 1 | 20 | RoW | SIM0417/Ritonavir, 750 mg SIM0417/100 mg ritonavir | Jiangsu Simcere Pharmaceutical Co., Ltd. | Elder | 09/23 | 11/23 | | |
NCT05731804: Hepatic Impairment and Renal Impairment Study of SIM0417 Combined With Ritonavir |
|
|
| Not yet recruiting | 1 | 72 | RoW | SIM0417 600 mg; Ritonavir100 mg, SIM0417 375 mg; Ritonavir100 mg, SIM0417 750 mg; Ritonavir100 mg | Jiangsu Simcere Pharmaceutical Co., Ltd. | Renal Impairment, Hepatic Impairment | 12/23 | 12/23 | | |
| Not yet recruiting | 1 | 24 | US | Magnetic Resonance (MR)-guided Laser Interstitial Thermal Therapy (LITT), MR-Guided LITT, Abacavir, Lamivudine, Ritonavir, Norvir, RTV, Temozolomide, TMZ, Focal Radiotherapy | University of Miami, Medtronic | High Grade Glioma | 05/28 | 05/29 | | |
NCT05679388: A Study of Extending Relugolix Dosing Intervals Through Addition of Itraconazole or Ritonavir in Prostate Cancer Patients |
|
|
| Terminated | 1 | 60 | US | Relugolix Pill, Ritonavir, Itraconazole, Sporanox | University of Chicago | Prostate Cancer, Prostate Cancer Metastatic, Prostate Adenocarcinoma | 08/24 | 08/24 | | |
ChiCTR2000030187: Clinical study for Lopinavir and Ritonavir in the treatment of novel coronavirus pneumonia (COVID-19) |
|
|
| Recruiting | N/A | 60 | | Lopinavir and Ritonavir Tablets ;Routine symptomatic support treatment | Jingzhou First People's Hospital; Jingzhou First People's Hospital, Self financing | Novel coronavirus pneumonia (COVID-19) | | | | |
ChiCTR2000029600: Clinical study for safety and efficacy of Favipiravir in the treatment of novel coronavirus pneumonia (COVID-19) |
|
|
| Recruiting | N/A | 90 | | alpha-Interferon atomization ;Lopinavir and Ritonavir + alpha-Interferon atomization ;Favipiravir + alpha-Interferon atomization | The Third People's Hospital of Shenzhen; The Third People's Hospital of Shenzhen, Self-financing | novel coronavirus pneumonia (COVID-19) | | | | |
ChiCTR2000030259: Evaluation Danoprevir sodium tablets combined with ritonavir in the treatment of novel coronavirus pneumonia (COVID-19): a randomized, open and controlled trial |
|
|
| Recruiting | N/A | 60 | | Danoprevir sodium tablets,/ritonavir oral ;Symptomatic treatment | Shanghai Changzheng Hospital; Shanghai Changzheng Hospital, Ascletis Pharmaceuticals CO., LTD. | Novel Coronavirus Pneumonia (COVID-19) | | | | |
| Completed | N/A | 32 | RoW | Atazanavir 300mg/ Ritonavir 100 mg once daily, Atazanavir 250 mg / ritonavir 80 mg | University of Liverpool, Infectious Diseases Institute, Makerere University College of Health Sciences, Joint Clinical Research Centre- Kampala, Desmond Tutu HIV Foundation, University of Cape Town, European and Developing Countries Clinical Trials Partnership (EDCTP) - funder | HIV/AIDS, Tuberculosis | 05/20 | 11/22 | | |
ChiCTR2000031734: Evaluation Danoprevir sodium tablets combined with ritonavir in the treatment of novel Coronavirus Pneumonia (COVID-19): a randomized, open-label, controlled trial |
|
|
| Recruiting | N/A | 40 | | Danoprevir sodium tablets,/ritonavir oral | Huoshenshan Hospital; Huoshenshan Hospital, Ascletis Pharmaceuticals CO., LTD. | Novel Coronavirus Pneumonia (COVID-19) | | | | |
ChiCTR2000030113: Randomized controlled trial for safety and efficacy of Favipiravir in the treatment of novel coronavirus pneumonia (COVID-19) with poorly responsive ritonavir/ritonavir |
|
|
| Recruiting | N/A | 30 | | Keep ritonavir/ritonavir treatment ;Favipiravir | The Third People's Hospital of Shenzhen; None, Self-financing | novel coronavirus pneumonia (COVID-19) | | | | |
ChiCTR2000030472: An open and controlled clinical study to evaluate the efficacy and safety of Ganovo combined with ritonavir in the treatment of novel coronavirus pneumonia (COVID-19) |
|
|
| Recruiting | N/A | 20 | | Ganovo/ ritonavir oral+conventional treatment ;Conventional treatment | Shenyang Sixth People's Hospita; Shenyang Sixth People's Hospital, Government | Novel Coronavirus Pneumonia (COVID-19) | | | | |
ChiCTR2200062889: A randomized, double-blind, placebo-control, efficacy and safety study of RAY1216 with or without Ritonavir in subjects with SARS-CoV-2 virus infection |
|
|
| Not yet recruiting | N/A | 60 | | RAY1216 ;placebo ;RAY1216 combined with ritonavir ;placebo | Sanya Central Hospital (Hainan Third People's Hospital); Sanya Central Hospita l(Hainan Third People's Hospital), Guangdong Raynovent Biotech Co., Ltd. | SARS-CoV-2 | | | | |
ChiCTR2300068546: Bioequvalence research of Nematavir Tablets/Ritonavir Ttablets (co-packaged) in healthy people (under fasting condition) |
|
|
| Not yet recruiting | N/A | 48 | | The first period of oral test preparation on an empty stomach, the elution period is 5 days, the second period of oral reference preparation on an empty stomach, the elution period is 5 days, and the third period of oral reference preparation on an empty stomach ;The first period of oral reference preparation on an empty stomach, with an elution period of 5 days, the second period of oral test preparation on an empty stomach, with an elution period of 5 days, and the third period of oral reference preparation on an empty stomach ;The first period of oral reference preparation on an empty stomach, with an elution period of 5 days, the second period of oral reference preparation on an empty stomach, with an elution period of 5 days, and the third period of oral test preparation on an empty stomach | Yue Bei People's Hospital; Yue Bei People's Hospital, Changsha Duzheng Biotechnology Co., Ltd. | Healthy people | | | | |
ChiCTR2300068913: Analysis and study on the rationality of clinical use of nimatralvir tables/ritonavir tables (co-packaged) |
|
|
| Not yet recruiting | N/A | 300 | | None | Dongying People's Hospital; Dongying People's Hospital, Self-funded | novel coronavirus pneumonia (COVID-19) | | | | |
NCT00537966: Characterization of Acute and Recent HIV-1 Infections in Zurich: a Long-term Observational Study |
|
|
| Recruiting | N/A | 2017 | Europe | Dolutegravir, Tivicay, Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Alafenamid Fumarate, Genvoya, Raltegravir, isentress, Darunavir, Prezista, Ritonavir, Norvir, Rilpivirine, Edurant, Lamivudine, 3TC, tenofovir, Viread, Emtricitabine, Emtriva, Abacavir, Ziagen | University of Zurich | HIV Infections | 01/25 | 01/25 | | |
NCT00476606: A Prospective Cohort of Children With HIV Infection |
|
|
| Active, not recruiting | N/A | 500 | RoW | Zidovudine, Stavudine, Didanosine, Lamivudine, Nevirapine, Efavirenz, LPV/r, Saquinavir, Indinavir, Ritonavir, Nelfinavir | The HIV Netherlands Australia Thailand Research Collaboration, Khon Kaen University | HIV Infections | 06/24 | 06/24 | | |
| Active, not recruiting | N/A | 40 | | | National Centre in HIV Epidemiology and Clinical Research, F. Hoffmann - La Roche Ltd | HIV | | | | |
ACTRN12618001036202: A Two-Part Study to Assess the Effects of Ritonavir on PRN1008 Pharmacokinetics, and the Effect of PRN1008 on QTc Interval Compared to Placebo and Moxifloxacin in Healthy Participants |
|
|
| Recruiting | N/A | 40 | | | Principia Biopharma, Inc., Principia Biopharma, Inc. | Pemphigus, Immune Thrombocytopenic Purpura | | | | |